Apellis’ application to market its complement C3 inhibitor Syfovre (pegcetacoplan) to treat geographic atrophy (GA) – a sight-robbing condition that accompanies age-related macular ...

Levels of FI achieved in VH from FOCUS subjects were then used in an in vitro simulated human vitreous complement activation assay, to gain insights on the therapeutic potencies of FI, C3 inhibitor ...

Apellis Pharmaceuticals (APLS) receives FDA approval of Syfovree for the treatment of geographic atrophy.

We recently compiled a list of the 10 Best Mid-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against ...

Apellis reported total revenues of $397 million for 2023, a sharp increase from $75 million in 2022, driven by SYFOVRE's launch and ongoing sales of EMPAVELI for paroxysmal nocturnal ...

This world-class speaker faculty will evaluate the entirety of the complement landscape, from scientific understanding to strategic, commercial intelligence. This means that no matter your role in ...

According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023. Through 2027, it is projected to grow at a ...

Pre-Open Stock Movers: Apellis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:APLS) 23% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority... Investing.com – U ...

Both Syfovre and Izervay must be injected directly into the eye once per month, or every other month, on an ongoing basis. They prevent damage to retinal cells by calming the immune response and ...